The funding will support the expansion of the Syn-One Test, a skin biopsy-based laboratory developed test for neurodegenerative diseases.
CND Life Sciences announced the completion of growth financing led by S-Curve Partners to expand its neurodiagnostics platform. The financing, which included participation from current investors and shareholders, is intended to accelerate the commercial trajectory and clinical adoption of the company’s Syn-One Test.
The Syn-One Test is a skin biopsy-based laboratory developed test designed to detect phosphorylated alpha-synuclein and other pathological markers. The platform assists clinicians in evaluating patients with suspected Parkinson disease, dementia with Lewy bodies, multiple system atrophy, and REM sleep behavior disorder, according to a press release from CND Life Sciences.
Since 2020, more than 4,000 neurologists and other clinicians across the United States have used the test to support the diagnostic evaluation of more than 60,000 patients. The platform is supported by peer-reviewed clinical evidence assessing cutaneous phosphorylated alpha-synuclein as a biomarker of synucleinopathies.
“S-Curve’s confidence in CND’s mission reflects the progress our team has made in expanding clinical adoption and advancing the science behind our scalable neurodiagnostics platform,” says Rick Morello, CEO, in a release.
Proceeds from the financing will support sustained growth of the platform, expansion of commercial initiatives, product innovation, and strategic partnerships. The company also plans to incorporate the test into a broader multimodal biomarker capability designed to support clinical diagnosis and disease characterization of neurodegenerative disorders.
“As a neurologist, I am encouraged to see the neuroscience field move toward multimodal biomarkers and earlier intervention,” says Todd Levine, MD, chief medical officer and co-founder, in a release. “This financing gives us the flexibility to invest in innovation, expand access to the Syn-One platform, and strengthen our pharmaceutical and research relationships.”
The financing arrives during a period of increased interest in objective biomarkers and precision medicine within the field of neurology.
“Neurodegenerative diseases remain among the most underdiagnosed and misdiagnosed conditions in medicine, and as disease-modifying therapies emerge, objective biomarkers will only become more essential for clinicians, patients, researchers, and pharmaceutical companies,” says Daniel Livschutz, founding partner of S-Curve Partners, in a release. “We believe CND has built one of the most differentiated platforms in neurodiagnostics, and this financing is intended to accelerate its evolution from a category-defining product to a broader platform supporting earlier diagnosis, disease differentiation, and more personalized care.”
